SCHEMBL26890923

SCHEMBL26890923

O=c1[nH]c(-c2ccccn2)nc2ccsc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPR P35270 4/20 0.66
▸ KRAS P01116 2/20 0.63
▸ RAB9A P51151 6/20 0.61
▸ NPC1 O15118 5/20 0.61
▸ LMNA P02545 4/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ HTT P42858 3/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.61
▸ GAA P10253 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ MAPT P10636 4/20 0.58
▸ SMN1; SMN2 Q16637 6/20 0.55
▸ PDE5A O76074 1/20 0.53
▸ PKM P14618 2/20 0.51
▸ METAP2 P50579 2/20 0.51
▸ METAP1 P53582 2/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MTOR P42345 1/20 0.51
▸ ADORA2A P29274 2/20 0.48
▸ ADORA1 P30542 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18702600 0.80 SPR (1.00) SPRKRASRAB9ANPC1LMNA
SCHEMBL2408228 0.79 SMN1; SMN2 (0.60) SPRKRASRAB9AALDH1A1HTT
SCHEMBL26158246 0.78 SPR (0.67) SPRKRASRAB9AL3MBTL1MAPT
SCHEMBL26676961 0.77 KRAS (1.00) SPRKRASRAB9ANPC1LMNA
SCHEMBL18997467 0.77 KRAS (0.56) KRASRAB9ANPC1LMNAALDH1A1
SCHEMBL14343746 0.77 NPC1 (0.57) SPRKRASRAB9ANPC1LMNA
SCHEMBL18702370 0.77 SPR (1.00) SPRKRASRAB9AMAPTSMN1; SMN2
SCHEMBL29764050 0.76 NPC1 (1.00) KRASRAB9ANPC1LMNAALDH1A1
SCHEMBL10709261 0.76 NPC1 (1.00) KRASRAB9ANPC1LMNAALDH1A1
SCHEMBL30169443 0.76 NPC1 (1.00) KRASRAB9ANPC1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416156-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING Remix Therapeutics Inc. (US) 2024-08-21 — — EP disclosed
EP-3642209-B1 COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY Therapeutics LLC (US) 2023-11-29 — — EP disclosed
WO-2023064879-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC. (US) 2023-04-20 — — WO disclosed
Send feedback